Bizarre Patents
Smoking Cessation Lighter and Method
A lighter for tobacco products suppresses the urge to smoke by operant conditioning.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7758868 | Modified polymerases and attenuated viruses and methods of use thereof The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable,... | 07/20/2010 |
| 7189401 | Live attenuated viruses for use as vectors or vaccines The present invention provides modified viral genomes for use as vaccines or vectors, which are improved in their ability to retain attenuating mutations. The genomes are from viruses that replicate by way of an RNA-dependent RNA or DNA polymerase. The genomes are m... | 03/13/2007 |
| 7138274 | Advanced oral poliovirus vaccine (Adv-OPV) deprived of the possibility of vaccine associated paralytic poliomyelities (VAPP) The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic nucleotide sequence of a parent Sabin type 1 poliovirus; (b) a nucleotide... | 11/21/2006 |
| 7101555 | Mycobacterial proteins, microorganisms producing them and their use for vaccines and the detection of tuberculosis Mycobacterium tuberculosis protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies. | 09/05/2006 |
| 7090855 | Prevention of Type 1 diabetes and other non-polio enterovirus diseases Live virus vaccines comprise attenuated viruses, while other vaccines comprise killed viruses or parts thereof. It has now been found that the immune response induced by oral poliovirus vaccine (OPV), which is a live vaccine, is cross-reactive with non-polio enterov... | 08/15/2006 |
| 7070781 | Nontoxic mucosal adjuvant A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating t... | 07/04/2006 |
| 7056521 | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT). ... | 06/06/2006 |
| 7008790 | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae A method of immunization, and compositions therefor, are provided for substantially preventing or reducing the symptoms of at least one infectious disease and at least one chronic immune mediated disorder. An immunogenic challenge which supplements the normal childh... | 03/07/2006 |
| 6887484 | Vaccine composition containing a promoter peptide A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a p... | 05/03/2005 |
| 6818222 | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT). ... | 11/16/2004 |
| 6756040 | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and where the antigen is adsorbed onto aluminum phosphate. The invention also relates to a multivalent vaccines, that is a vaccine for the amelioratio... | 06/29/2004 |
| 6676945 | Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis Mycobacterium tuberculosis protein having a molecular weight of 28.779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.... | 01/13/2004 |
| 6664099 | Method for the preservation of viruses and mycoplasma A biologically-active material comprising a live virus or mycoplasma is preserved by a method of desiccation, without lyophilisation, in a matrix of glassy trehalose having a residual moisture content of not greater than 2%. The method comprises two vacuu... | 12/16/2003 |
| 6620414 | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination... | 09/16/2003 |
| 6420139 | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae A method of immunization, and compositions therefor, are provided for substantially preventing or reducing the symptoms of at least one infectious disease and at least one chronic immune mediated disorder. An immunogenic challenge which supplements the no... | 07/16/2002 |
| 6416762 | Anti-picornaviral ligands via a combinatorial computational and synthetic approach The present invention provides structure-based combinatorial libraries of compounds containing the functional group minima of picornaviruses including poliovirus and rhinovirus. The libraries can be used to screen for therapeutical antiviral compounds, e.... | 07/09/2002 |
| 6136570 | Method for producing RNA viruses from cDNA The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that... | 10/24/2000 |
| 6063384 | Encapsidated recombinant viral nucleic acid and methods of making and using same The present invention pertains to a method of encapsidating a recombinant poliovirus nucleic acid to obtain a yield of encapsidated viruses which substantially comprises encapsidated recombinant poliovirus nucleic acid. The method of encapsidating a recom... | 05/16/2000 |
| 6051238 | Stabilizers for lyophilized mumps vaccines Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric alcohol (such as sorbitol), an increase amount of a disaccharide... | 04/18/2000 |
| 6045802 | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a... | 04/04/2000 |
| 6039959 | Treatment and diagnosis of infections due to helicobacter pylori The present invention provides agents for the detection of urease from H. pylori, and agents and epitopes for use in the treatment or diagnosis of infection due to H. pylori, as well as diagnostic tests and kits therefor and the use of the agents and epit... | 03/21/2000 |
| 6013264 | Vaccine Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37° C. and is highly immunogenic, for example when the vaccine is administered to inf... | 01/11/2000 |
| 5965124 | Replication-competent recombinant viral vaccines and method of producing same Replication-competent recombinant viruses, particularly replication-competent recombinant polioviruses, which include (1) exogenous nucleic acid sequences which encode an exogenous polypeptide and (2) a nucleic acid sequence which encodes an artificial pr... | 10/12/1999 |
| 5911998 | Method of producing a virus vaccine from an African green monkey kidney cell line A method for producing novel African Green Monkey Kidney (AGMK) cell lines is taught. These cell lines which are free of viable adventitious microbial agents are useful as substrates for viruses and for the preparation of viral vaccines.... | 06/15/1999 |
| 5858375 | Pharmaceutical compositions containing D2 O A pharmaceutical composition comprises a solution or suspension of a biological agent in a diluent comprising D2 O, which solution or suspension contains sufficient amounts of a sugar, phosphate, glutamic acid or a physiologically acceptable sa... | 01/12/1999 |
| 5837269 | Vaccine compositions and method for enhancing an immune response The invention relates to a vaccine which comprises an antigen and an immune response augmenting agent. The immune response augmenting agent is capable of enhancing T cell lymphokine production. Suitable immune response augmenting agents include, but are n... | 11/17/1998 |
| 5834302 | Method for producing RNA viruses from CDNA The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that... | 11/10/1998 |
| 5807757 | Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation A method is provided for preparing polyphosphazene microspheres wherein the polyphosphazene microspheres are produced by coacervation. A solution containing a polyphosphazene is admixed with a solution containing a salt of a monovalent ion such as a salt ... | 09/15/1998 |
| 5762940 | Methods and compositions for inhibiting or destroying viruses or retroviruses This invention relates to a method and composition for inhibiting or destroying viruses or retroviruses in a mammalian host. The method comprises contacting the viruses or retroviruses with a composition. The composition comprises an active ingredient cap... | 06/09/1998 |
| 5728385 | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae A method of immunization, and compositions therefor, are provided for substantially preventing or reducing the symptoms of at least one infectious disease and at least one chronic immune mediated disorder. An immunogenic challenge which supplements the no... | 03/17/1998 |
| 5728519 | Assay for virulent revertants of attenuated live vaccines and kits therefor The present invention provides a method of classifying an unclassified live poliovirus vaccine as having an acceptable or unacceptable level of neurovirulence, comprising, prior to vaccine administration, the steps of: a) selectively amplifying a region o... | 03/17/1998 |
| 5683901 | Method of producing RNA viruses from cDNA The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that... | 11/04/1997 |
| 5639462 | Attenuated polyiviruses vaccine containing them and vaccination methods using them An attenuated poliovirus in which the 5' non-coding region of the genome is: (a) the 5' non-coding region of poliovirus type 3 Leon strain modified by the provision of the bases uracil and adenine at positions 472 and 537 thereof respectively, or (b) the ... | 06/17/1997 |
| 5622705 | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same The present invention pertains to a method of encapsidating a recombinant poliovirus nucleic acid to obtain a yield of encapsidated viruses which substantially comprises encapsidated recombinant poliovirus nucleic acid. The method of encapsidating a recom... | 04/22/1997 |
| 5618539 | Stabilized vaccine compositions Non-lyophilized vaccine compositions which contain a poliovirus and, as stabilizer, a compound containing at least two amino or imine groups. The stabilizers include polyimines such as the amino acid lysine or ethylenediamine and polyimines such as poly(e... | 04/08/1997 |
| 5562910 | Vaccine compositions and method for enhancing an immune response The invention relates to a vaccine which comprises an antigen and an immune response augmenting agent. The immune response augmenting agent is capable of enhancing T cell lymphokine production. Suitable immune response augmenting agents include, but are n... | 10/08/1996 |
| 5550018 | Test for virulent genomic nucleotide 472 revertants in attenuated live poliovirus type 3 vaccines The present invention comprises the method of evaluation of the safety of live attenuated vaccines based on detection and measurement of the incidence of genetic changes associated with reversion to virulence in vaccine microorganisms. The method based on... | 08/27/1996 |
| 5529777 | Hydrogel microencapsulated vaccines Water soluble polymers or polymeric hydrogels are used to encapsulate antigen to form vaccines. The antigen is mixed with a polymer solution, microparticles are formed of the polymer and antigen, and, optionally, the polymer is crosslinked to form a stabl... | 06/25/1996 |
| 5525715 | Method for producing RNA viruses from cDNA The present invention relates to methods for producing RNA virus cDNA, methods for producing viable, RNA virus and viable, RNA virus produced by those methods. The invention also related to a novel RNA virus cDNA, recombinant DNA molecules containing that... | 06/11/1996 |
| 5518725 | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination The invention relates to a vaccine which comprises an antigen and a lymphoid organ modifying agent. Suitable lymphoid organ modifying agents include 1,25-dihydroxy Vitamin D3, biologically active Vitamin D3 derivatives which are capa... | 05/21/1996 |
